HONG KONG – With $13.2 million in new financing, Tokyo-based oncology drug developer Anaeropharma Science Inc. now plans to focus on research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium. Read More

A new deal giving Celgene Corp. strategically important rights to a PD-1 inhibitor developed by Beijing-based Beigene Ltd. will tightly bond the companies' fortunes in both the U.S. and China, putting Celgene in charge of development and commercialization of a key Beigene asset, while Beigene takes charge of selling Celgene's top products in China and advancing new ones. Read More

An international research collaboration has found a means to improve the effect of mimetics of the second mitochondrial-derived activator of caspase (Smac), a novel class of targeted cancer drugs that act by inducing apoptotic cancer cell death and inhibiting pro-survival signaling. Read More

HONG KONG – India's Central Drugs Standard Control Organization (CDSCO) has been streamlining regulations to standardize its rules on the market for pharmaceuticals. Read More

HONG KONG – Facing increased U.S. regulatory scrutiny, India's largest drugmaker, Sun Pharmaceutical Industries Ltd., is outsourcing some of its manufacturing in a deal that provides South Korea's Samsung Biologics Co. Ltd., the biologics manufacturing arm of the Samsung conglomerate, an opportunity to expand its market share. Read More

GUANGZHOU, China – China's health care reforms have made great strides toward developing the country's pharmaceutical industry, but the current ecosystem may not be enough for China to compete on the world stage of drug development, said industry experts and regulators at this week's GF Securities Life Sciences Investment Conference. Read More

Cynata Therapeutics Ltd., of Melbourne, Australia, said, following a pre-investigational new drug meeting with the FDA's Office of Cellular, Tissue and Gene Therapies, it has received written advice from the agency on the regulatory approval path for its Cymerus mesenchymal stem cell (MSC) products in the U.S. The FDA confirmed that the scope and substance of the company's chemistry, manufacturing and controls dossier is commensurate with its expectations, which indicates that Cymerus MSC products are expected to be of suitable quality for clinical trial use. Read More